Travere Therapeutics, Inc. (TVTX) News
Follow Travere Therapeutics, Inc. (TVTX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 22 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Form SCHEDULE 13G/A Travere Therapeutics, Filed by: FMR LLC
Filed on: November 5, 20
EQUITY | Nov 05, 2026, 06:27 PM UTC
M
Camurus Q3 revenue beats estimates on Buvidal, Brixadi growth
EQUITY | Nov 05, 2026, 06:18 AM UTC
M
Travere Therapeutics Swings to Q3 Loss as Revenue Rises
EQUITY | Nov 02, 2026, 10:30 PM UTC
M
Travere Therapeutics Reports Nine-Month Revenue of $224.56M, Net Loss of $52.34M
Revenue for the first nine months of 2026 rose 36.2% from a year earlier; diluted EPS was a loss of $0.55.
EARNINGS | Nov 02, 2026, 09:51 PM UTC
M
Travere Therapeutics Q3 2026 Earnings Call Begins
Travere Therapeutics' quarterly earnings call has begun.
EQUITY | Nov 02, 2026, 09:27 PM UTC
M
Travere Therapeutics swings to Q3 net loss of $52.34 million
EQUITY | Nov 02, 2026, 09:18 PM UTC
L
Travere Therapeutics Reports Q3 Net Income
EARNINGS | Nov 02, 2026, 09:03 PM UTC
M
Travere Therapeutics Reports Third-Quarter 2026 Results
Travere reported FILSPARI net product sales of $200 million for the quarter and provided a corporate update.
EQUITY | Nov 02, 2026, 09:03 PM UTC
M
Travere Therapeutics Q3 EPS: USD -0.55
EARNINGS | Nov 02, 2026, 09:02 PM UTC
M
Travere Therapeutics Q3'26 Earnings Preview
Travere Therapeutics is scheduled to report Q3'26 results on October 22. The report time is not specified.
EQUITY | Oct 15, 2026, 11:01 AM UTC
L
Weekly Recap: Sparsentan patent allowance and CEO succession
Travere Therapeutics, Inc. (NASDAQ:TVTX) won a USPTO Notice of Allowance for sparsentan methods and plans to seek issuance and FDA Orange Book listing while management shifts as CEO Eric Dube steps down Dec. 1, 2026 for
REGULATION | Sep 28, 2026, 11:07 AM UTC
L
Travere Therapeutics Is Maintained at Buy by Guggenheim
Ratings actions from Benzinga: GMT) Travere Therapeutics Price Target Raised to $89.00/Share From $75.00 by GuggenheimRatings actions from Benzinga
NEWS | Sep 24, 2026, 01:06 PM UTC
L
Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Travere Therapeutics, Inc. NASDAQ:TVTX
NEWS | Sep 23, 2026, 11:05 AM UTC
L
Travere Therapeutics, Inc. (TVTX) Gets USPTO Allowance for FILSPARI FSGS Method Patent to 2037
Travere said the USPTO issued a Notice of Allowance for a U.S. patent application covering certain methods of using FILSPARI (sparsentan) in FSGS, with protection expected into Oct 2037. The company plans to list the pat
REGULATION | Sep 23, 2026, 11:00 AM UTC
L
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled “Biphenyl Sulfonamide C
NEWS | Sep 23, 2026, 11:00 AM UTC
M
Travere Therapeutics names Bradley Campbell CEO effective Dec. 1
Travere Therapeutics appointed Bradley Campbell as president and chief executive officer, effective Dec. 1, as Eric Dube steps down to focus on health and family.
EQUITY | Sep 21, 2026, 08:25 PM UTC
L
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Travere Therapeutics, Inc. NASDAQ:TVTX
NEWS | Sep 11, 2026, 09:03 PM UTC
H
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Wednesday. Shares of Wynn Resorts Ltd (NASDAQ: WYNN ) rose sharply after the company reported better-than- expected quarterly financial resul
EARNINGS | Aug 05, 2026, 02:01 PM UTC
L
TVTX Sees Robust FILSPARI Demand
TVTX reports strong FILSPARI sales growth
EARNINGS | Aug 04, 2026, 08:14 PM UTC
M
TVTX: Guggenheim Raises Target
Guggenheim analyst Vamil Divan maintains a Buy rating on Travere Therapeutics and raises the price target to $65
EQUITY | Jun 25, 2026, 02:19 PM UTC
M
TVTX: Guggenheim Raises PT
Guggenheim analyst Vamil Divan raises price target on Travere Therapeutics to $65 and keeps Buy rating ahead of Q2 earnings
EQUITY | Jun 25, 2026, 12:13 PM UTC
M
TVTX: Wedbush Raises Target
Wedbush maintains Outperform on Travere Therapeutics and raises price target to $61
EQUITY | Jun 22, 2026, 01:00 PM UTC